Wall Street brokerages predict that Immunic (NASDAQ:IMUX) will announce ($0.62) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Immunic’s earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.57). Immunic posted earnings per share of ($1.52) during the same quarter last year, which suggests a positive year-over-year growth rate of 59.2%. The company is scheduled to report its next quarterly earnings report before the market opens on Thursday, August 13th.
On average, analysts expect that Immunic will report full year earnings of ($3.06) per share for the current financial year, with EPS estimates ranging from ($4.30) to ($2.44). For the next year, analysts expect that the business will report earnings of ($2.75) per share, with EPS estimates ranging from ($3.31) to ($2.23). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Immunic.
Immunic (NASDAQ:IMUX) last issued its earnings results on Friday, May 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.96) by $0.17.
A number of analysts have recently weighed in on the company. BMO Capital Markets assumed coverage on Immunic in a research note on Monday, July 20th. They set an “outperform” rating and a $40.00 price objective for the company. ValuEngine lowered Immunic from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 11th. Wedbush reissued a “buy” rating and set a $58.00 price objective on shares of Immunic in a research note on Monday, July 27th. Zacks Investment Research lowered Immunic from a “buy” rating to a “hold” rating in a research note on Tuesday, June 23rd. Finally, BidaskClub raised Immunic from a “hold” rating to a “buy” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Immunic currently has an average rating of “Buy” and a consensus target price of $39.83.
Shares of IMUX opened at $17.20 on Friday. The firm has a market cap of $257.45 million, a P/E ratio of -4.66 and a beta of 3.17. The stock has a 50 day simple moving average of $13.60 and a two-hundred day simple moving average of $9.83. Immunic has a 1 year low of $4.19 and a 1 year high of $17.81.
In related news, COO Manfred Groeppel sold 5,650 shares of the stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $14.58, for a total transaction of $82,377.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Vitt sold 6,300 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $14.68, for a total value of $92,484.00. The disclosure for this sale can be found here. 12.07% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. International Biotechnology Trust PLC purchased a new stake in shares of Immunic during the second quarter valued at $1,531,000. Wells Fargo & Company MN boosted its position in Immunic by 78.9% in the first quarter. Wells Fargo & Company MN now owns 10,814 shares of the company’s stock worth $65,000 after purchasing an additional 4,769 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Immunic by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,631 shares of the company’s stock worth $588,000 after purchasing an additional 18,602 shares during the last quarter. 14.41% of the stock is currently owned by institutional investors.
Immunic Company Profile
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Read More: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.